Free Trial
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free CMND Stock Alerts

Clearmind Medicine (CMND) Competitors

Clearmind Medicine logo
$3.28 -0.06 (-1.65%)
As of 11:37 AM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

CMND vs. LIAN, FNCH, SNGX, MTEX, and PHXM

Should you buy Clearmind Medicine stock or one of its competitors? MarketBeat compares Clearmind Medicine with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Clearmind Medicine include LianBio (LIAN), Finch Therapeutics Group (FNCH), Soligenix (SNGX), Mannatech (MTEX), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry.

How does Clearmind Medicine compare to LianBio?

LianBio (NASDAQ:LIAN) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends, media sentiment and valuation.

In the previous week, Clearmind Medicine had 5 more articles in the media than LianBio. MarketBeat recorded 5 mentions for Clearmind Medicine and 0 mentions for LianBio. Clearmind Medicine's average media sentiment score of 0.97 beat LianBio's score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Overall Sentiment
LianBio Neutral
Clearmind Medicine Positive

LianBio's return on equity of -33.17% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
LianBioN/A -33.17% -30.19%
Clearmind Medicine N/A -207.53%-100.70%

74.8% of LianBio shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

LianBio is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LianBioN/AN/A-$110.29M-$0.81N/A
Clearmind MedicineN/AN/A-$3.86M-$197.20N/A

LianBio has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market.

Summary

Clearmind Medicine beats LianBio on 6 of the 10 factors compared between the two stocks.

How does Clearmind Medicine compare to Finch Therapeutics Group?

Finch Therapeutics Group (NASDAQ:FNCH) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

21.8% of Finch Therapeutics Group shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Finch Therapeutics Group has a beta of 1.18, meaning that its share price is 18% more volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Finch Therapeutics Group is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Finch Therapeutics GroupN/AN/A-$74.75M-$8.82N/A
Clearmind MedicineN/AN/A-$3.86M-$197.20N/A

In the previous week, Clearmind Medicine had 5 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 5 mentions for Clearmind Medicine and 0 mentions for Finch Therapeutics Group. Clearmind Medicine's average media sentiment score of 0.97 beat Finch Therapeutics Group's score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Overall Sentiment
Finch Therapeutics Group Neutral
Clearmind Medicine Positive

Finch Therapeutics Group's return on equity of -69.14% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Finch Therapeutics GroupN/A -69.14% -26.92%
Clearmind Medicine N/A -207.53%-100.70%

Summary

Finch Therapeutics Group and Clearmind Medicine tied by winning 5 of the 10 factors compared between the two stocks.

How does Clearmind Medicine compare to Soligenix?

Soligenix (NASDAQ:SNGX) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Soligenix currently has a consensus price target of $6.00, indicating a potential upside of 1,292.11%. Given Soligenix's stronger consensus rating and higher probable upside, analysts clearly believe Soligenix is more favorable than Clearmind Medicine.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Soligenix
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, Clearmind Medicine had 3 more articles in the media than Soligenix. MarketBeat recorded 5 mentions for Clearmind Medicine and 2 mentions for Soligenix. Clearmind Medicine's average media sentiment score of 0.97 beat Soligenix's score of 0.30 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Overall Sentiment
Soligenix Neutral
Clearmind Medicine Positive

Clearmind Medicine's return on equity of -207.53% beat Soligenix's return on equity.

Company Net Margins Return on Equity Return on Assets
SoligenixN/A -244.73% -131.22%
Clearmind Medicine N/A -207.53%-100.70%

Soligenix has a beta of 1.84, indicating that its stock price is 84% more volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

3.6% of Soligenix shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 3.1% of Soligenix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Soligenix is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SoligenixN/AN/A-$11.08M-$1.68N/A
Clearmind MedicineN/AN/A-$3.86M-$197.20N/A

Summary

Clearmind Medicine beats Soligenix on 7 of the 13 factors compared between the two stocks.

How does Clearmind Medicine compare to Mannatech?

Mannatech (NASDAQ:MTEX) and Clearmind Medicine (NASDAQ:CMND) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, earnings, risk, dividends, analyst recommendations, profitability and media sentiment.

Mannatech has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Clearmind Medicine has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Clearmind Medicine has lower revenue, but higher earnings than Mannatech. Mannatech is trading at a lower price-to-earnings ratio than Clearmind Medicine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mannatech$108.04M0.10-$15.21M-$6.71N/A
Clearmind MedicineN/AN/A-$3.86M-$197.20N/A

In the previous week, Clearmind Medicine had 3 more articles in the media than Mannatech. MarketBeat recorded 5 mentions for Clearmind Medicine and 2 mentions for Mannatech. Clearmind Medicine's average media sentiment score of 0.97 beat Mannatech's score of 0.93 indicating that Clearmind Medicine is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mannatech
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Clearmind Medicine
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Clearmind Medicine has a net margin of 0.00% compared to Mannatech's net margin of -11.97%. Clearmind Medicine's return on equity of -207.53% beat Mannatech's return on equity.

Company Net Margins Return on Equity Return on Assets
Mannatech-11.97% -2,383.34% -40.24%
Clearmind Medicine N/A -207.53%-100.70%

13.0% of Mannatech shares are owned by institutional investors. Comparatively, 96.1% of Clearmind Medicine shares are owned by institutional investors. 41.5% of Mannatech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mannatech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Clearmind Medicine
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Clearmind Medicine beats Mannatech on 7 of the 13 factors compared between the two stocks.

How does Clearmind Medicine compare to PHAXIAM Therapeutics?

Clearmind Medicine (NASDAQ:CMND) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings and institutional ownership.

96.1% of Clearmind Medicine shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 1.9% of PHAXIAM Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Clearmind Medicine has a beta of 0.64, meaning that its stock price is 36% less volatile than the broader market. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, meaning that its stock price is 135% more volatile than the broader market.

In the previous week, Clearmind Medicine had 5 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 5 mentions for Clearmind Medicine and 0 mentions for PHAXIAM Therapeutics. Clearmind Medicine's average media sentiment score of 0.97 beat PHAXIAM Therapeutics' score of 0.00 indicating that Clearmind Medicine is being referred to more favorably in the media.

Company Overall Sentiment
Clearmind Medicine Positive
PHAXIAM Therapeutics Neutral

PHAXIAM Therapeutics' return on equity of 0.00% beat Clearmind Medicine's return on equity.

Company Net Margins Return on Equity Return on Assets
Clearmind MedicineN/A -207.53% -100.70%
PHAXIAM Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Clearmind MedicineN/AN/A-$3.86M-$197.20N/A
PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A

Summary

PHAXIAM Therapeutics beats Clearmind Medicine on 5 of the 8 factors compared between the two stocks.

Get Clearmind Medicine News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMND and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMND and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMND vs. The Competition

Export
MetricClearmind MedicineMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.35M$2.98B$6.50B$12.32B
Dividend YieldN/A1.76%2.67%5.66%
P/E Ratio-0.0218.8024.0024.65
Price / SalesN/A464.19543.88171.03
Price / CashN/A55.8827.4837.92
Price / Book0.234.0110.736.84
Net Income-$3.86M$75.79M$3.56B$337.45M
7 Day Performance-13.32%2.41%1.34%2.48%
1 Month Performance-36.83%0.13%2.25%4.36%
1 Year Performance-99.04%24.17%26.20%32.45%

Clearmind Medicine Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMND
Clearmind Medicine
3.4013 of 5 stars		$3.29
-1.6%		N/A-99.0%$3.35MN/AN/AN/A
LIAN
LianBio
N/A$0.11
flat		N/A-57.9%$11.91MN/AN/A110
FNCH
Finch Therapeutics Group
N/A$7.30
flat		N/AN/A$11.72MN/AN/A190
SNGX
Soligenix
2.0035 of 5 stars		$0.48
-35.5%		$6.00
+1,142.0%		-76.1%$11.10M$120KN/A20
MTEX
Mannatech
1.7583 of 5 stars		$5.77
+1.2%		N/A-41.5%$11M$108.04MN/A250

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMND) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel